Is Foundayo available in the UK? MHRA licence, private prescription and NHS status

Foundayo, Eli Lilly's once-daily weight-loss tablet, was approved in the United States on 1 April 2026 and licensed in the United Kingdom by the MHRA on 10 August 2026 — the first authorisation anywhere in Europe. Since 24 August 2026 it has been available here by private prescription. It is not available on the NHS, and will not be unless NICE recommends it. This page sets out exactly where the UK position stands, what has to happen before anyone can be prescribed it on the NHS, and — because part of the answer still involves uncertainty — which dates are confirmed and which are not.

Where things stand: approved in the US, licensed in the UK

The confirmed facts are straightforward. The US Food and Drug Administration approved Foundayo (generic name orforglipron) on 1 April 2026, for adults with obesity — or some adults with overweight who also have weight-related medical problems — to reduce excess body weight and keep it off, alongside a reduced-calorie diet and increased physical activity. The approval moved unusually quickly: it went through the FDA's National Priority Voucher pilot and cleared roughly 50 days after filing.

Interest in the drug is not hard to explain. In its main phase 3 trial, published in the New England Journal of Medicine, the highest study dose produced an average 12.4% body-weight reduction over 72 weeks, against 0.9% with placebo, and 39.6% of participants on that dose lost at least 15% of their body weight — results delivered by a once-daily tablet that can be taken at any time of day, with no food or water restrictions. You can read more about how the drug came to exist on our development and history page.

For the UK, the wait turned out to be shorter than most commentary expected. On 10 August 2026 the MHRA — the Medicines and Healthcare products Regulatory Agency, the UK's medicines regulator — granted Foundayo a marketing authorisation, making the UK the first country in Europe to license orforglipron. The licence covers two uses: weight management in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition; and type 2 diabetes. The Summary of Product Characteristics for each of the six strengths is published on the electronic medicines compendium (emc). Two weeks later, on 24 August 2026, Lilly UK announced that the medicine was available in the UK via private prescription.

What the MHRA licence does and does not settle

The MHRA assesses whether a medicine's quality, safety and efficacy justify a UK licence (formally, a marketing authorisation). The UK decision landed roughly four months after the US one — well ahead of the "late 2026 to early 2027" window that circulated in industry commentary through the summer, which is a useful reminder that such forecasts are exactly that. The licence sets out the approved uses, the six tablet strengths and the dosing schedule. It says nothing about price, and nothing about NHS funding: those are separate questions, covered below.

The UK timeline, stage by stage

Two separate gates stand between a new medicine and a patient in the UK. The first is the MHRA licence, which Foundayo now has. The second — for NHS availability — is a NICE appraisal, which is under way. They run in sequence, which is why "licensed" and "available on the NHS" can sit months or more apart.

Private availability came first

Private prescribing does not have to wait for the NICE process, because NICE decides NHS funding rather than whether a licensed medicine may be prescribed at all. That is exactly what has happened: Lilly UK announced private-prescription availability on 24 August 2026, a fortnight after the licence. Foundayo is a prescription-only medicine — a prescriber has to assess whether it is clinically appropriate for you, within the licensed uses, and is free to conclude that it is not. On cost: private prices vary between regulated providers, and it is worth checking what a fee includes. This site does not quote prices or name providers.

NHS access runs through NICE

For NHS prescribing, a licence is only step one. NICE — the National Institute for Health and Care Excellence — must appraise whether the drug is clinically effective and cost-effective for NHS use. That appraisal is under way: NICE lists "Orforglipron for managing overweight and obesity" (appraisal ID6516) as in development, with publication expected on 18 November 2026. If NICE says yes, NHS England normally has to make the medicine available within about three months of final guidance — and, going by how Mounjaro and Wegovy were handled, any recommendation would likely be restricted to defined groups, such as people above certain BMI thresholds with weight-related conditions, rather than open access. For a sense of how tight those rules can be: NHS GP prescribing of Mounjaro is currently limited, under NHS England's phased roll-out, to people with a BMI of 35 or more (adjusted down for some ethnic backgrounds) plus at least four of five qualifying weight-related conditions. If you are hoping to get Foundayo on the NHS, it is worth calibrating expectations now: a NICE recommendation is not guaranteed, and even a positive one is likely to come with strict eligibility criteria.

Prescription only: how legitimate UK supply works

Now that Foundayo is licensed, the question has changed from "can it be sold at all?" to "is this seller legitimate?". Foundayo is a prescription-only medicine, so lawful UK supply always involves a consultation and a prescription from a qualified prescriber, dispensed by a regulated pharmacy. Anyone offering "Foundayo" or "orforglipron" to UK customers without that is acting unlawfully — and whatever arrives in the post cannot be assumed to be a genuine, quality-assured medicine.

If you are trying to judge whether an online offer could possibly be legitimate, the following signs settle the question:

• No prescriber involvement. Genuine UK supply of prescription-only medicines always involves a prescription from a qualified prescriber. "No consultation needed" means unlawful supply, licence or no licence.
• Unregistered sellers. Legitimate UK pharmacies are registered with the General Pharmaceutical Council (or the Pharmaceutical Society of Northern Ireland), and online prescribing services in England are regulated by the Care Quality Commission. Social-media sellers and marketplace listings are not.
• Pressure tactics. Countdown timers, crypto or bank-transfer payment, and prices that seem surprisingly good should all be read the same way: an offer dressed up with urgency is an offer to avoid.

The practical consequence is worth spelling out. A product bought outside the legal supply chain has never passed through the quality-assurance system that a licence exists to enforce, so there is no reliable way to know what tablets sold that way actually contain. If you come across a site selling "Foundayo" to UK buyers without a prescription, you can report it to the MHRA, which investigates illegal medicine sales. And if you have taken any weight-loss medicine and experienced side effects, report them through the MHRA Yellow Card scheme and speak to your GP or pharmacist. Our side-effects page explains what was actually reported in the clinical trials, which is a useful baseline for that conversation.

What UK readers can usefully do now

If weight is affecting your health, the NHS obesity pages set out the options that already exist, from structured support to the weight-loss medicines available on the NHS — and your GP can tell you which, if any, are appropriate for you, including whether you meet the current NHS criteria for weight-loss injections. Foundayo is one option among several for a prescriber to weigh, not an automatic upgrade, and for now it is a private one.

If you want to understand the drug itself, the most concrete thing about it is how it is dosed: six licensed tablet strengths, started low and increased slowly, with at least a month at each step, to limit stomach-related side effects. Our dosage and titration guide walks through the schedule in detail.

Frequently asked questions

References

1. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss. Investor news release, April 2026. investor.lilly.com
2. US Food and Drug Administration. NDA 220934 approval letter, 1 April 2026. accessdata.fda.gov
3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist — ATTAIN-1 phase 3 results. New England Journal of Medicine. nejm.org
4. Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. Press release, 10 August 2026. gov.uk
5. Eli Lilly and Company (UK). Press releases — Foundayo available in the UK via private prescription, 24 August 2026. lilly.com/uk
6. Foundayo — Summary of Product Characteristics. electronic medicines compendium (emc). medicines.org.uk
7. National Institute for Health and Care Excellence. Orforglipron for managing overweight and obesity — technology appraisal in development (GID-TA11650 / ID6516), expected publication 18 November 2026. nice.org.uk
8. NHS England. Interim commissioning guidance — NICE TA1026 tirzepatide (updated 2 April 2026). england.nhs.uk
9. Medicines and Healthcare products Regulatory Agency (MHRA) — the UK medicines regulator. gov.uk
10. NHS. Obesity — overview and treatment options. nhs.uk
11. MHRA Yellow Card scheme — report suspected side effects from any medicine. yellowcard.mhra.gov.uk